Drug intelligence / Profile preview

ruscogenin

Development stage
Preclinical
Modality
Small Molecules, Peptides
Administration
Topical, Rectal, Oral
01

Overview

Ruscogenin is a steroidal sapogenin primarily isolated from the plants *Ruscus aculeatus* (butcher’s broom) and *Ophiopogon japonicus*. It exhibits multiple pharmacological activities including anti-inflammatory, anti-thrombotic, vasoconstrictive, and circulation-enhancing effects[1][2][4][5]. Ruscogenin has been used in combination with local anesthetics for the treatment of hemorrhoids and for local anesthesia[2]. Its mechanisms of action include inhibition of nuclear factor kappa B (NF-κB) signaling pathways, suppression of intercellular adhesion molecule-1 (ICAM-1) expression, reduction in leukocyte migration and reactive oxygen species generation, as well as modulation of mitogen-activated protein kinase (MAPK) pathways[1][4][7][8]. It also demonstrates vasoconstrictive properties via adrenergic mechanisms—possibly involving alpha-adrenergic receptors—and reduces cell permeability through anti-elastase activity[5]. Experimental studies suggest potential therapeutic applications in acute lung injury, pulmonary hypertension, cerebral ischemia-induced blood-brain barrier dysfunction after stroke, pancreatitis-related inflammation and edema reduction[1][7][8].

Other names
(1β,3β,25R)-Spirost-5-ene-1,3-diol
02

Targets

ADRA1 (Alpha-1 adrenergic receptor family)NF-κBElastaseICAM1 (Intercellular Adhesion Molecule 1)

Beyond the preview

Go deeper on ruscogenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruscogenin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call